Kangho Suh1, Brian J Cole2, Andreas Gomoll3, Seung-Mi Lee4, Hangseok Choi5, Chul-Won Ha6, Hong Chul Lim7, Myung Ku Kim8, Gwi-Yeom Ha5, Dong-Churl Suh5. 1. Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 15217, USA. kas551@pitt.edu. 2. Department of Orthopedic Surgery, Rush Oak Park Hospital, Rush Medical College, Chicago, IL, USA. 3. Department of Orthopedic Surgery, Hospital for Special Surgery, Weill-Cornell Medical College, New York, NY, USA. 4. Daegu Catholic University College of Pharmacy, Gyeongsan-si, Gyeongbukdo, South Korea. 5. Chung-Ang University College of Pharmacy, Seoul, South Korea. 6. Sungkwunkwan University Samsung Seoul Hospital, Seoul, South Korea. 7. Seoul Baronsesang Hospital, Seoul, South Korea. 8. Inha University School of Medicine, Incheon, South Korea.
Abstract
OBJECTIVES: The aim of this study was to assess the cost effectiveness of allogeneic umbilical cord blood-derived mesenchymal stem cells with sodium hyaluronate (hUCB-MSC) compared with microfracture in patients with knee cartilage defects caused by osteoarthritis (OA) in South Korea. METHODS: A partitioned survival model approach was taken consisting of five mutually exclusive health states: excellent, good, fair, poor, and death over a 20-year time horizon. Utility values were obtained from a randomized clinical trial. Cost data were extracted from a database provided by the Health Insurance Review & Assessment Service, and the utilization of healthcare services was estimated from an expert panel of orthopedic surgeons using a structured questionnaire. The incremental cost-effectiveness ratio (ICER) in terms of quality-adjusted life-years (QALY) was calculated. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: In the base case, the incremental costs of US$14,410 for hUCB-MSC therapy along with its associated QALY gain of 0.857 resulted in an ICER of US$16,812 (₩18,790,773) per QALY (95% confidence interval [CI] US$13,408-US$20,828) when compared with microfracture treatment from a healthcare payer perspective. From a societal perspective, the ICER was US$268 (₩299,255) per QALY (95% CI -US$2915 to US$3784). When using a willingness-to-pay threshold of US$22,367/QALY, the probability of hUCB being cost effectiveness compared with microfracture was 99% from the healthcare payer perspective and 100% from the societal perspective. CONCLUSIONS: The study demonstrated that hUCB-MSC therapy was cost effective compared with microfracture when treating patients with knee OA. These findings should inform health policy decision makers about considerations for cost-effective therapy for treating knee OA to ultimately enhance population health.
OBJECTIVES: The aim of this study was to assess the cost effectiveness of allogeneic umbilical cord blood-derived mesenchymal stem cells with sodium hyaluronate (hUCB-MSC) compared with microfracture in patients with knee cartilage defects caused by osteoarthritis (OA) in South Korea. METHODS: A partitioned survival model approach was taken consisting of five mutually exclusive health states: excellent, good, fair, poor, and death over a 20-year time horizon. Utility values were obtained from a randomized clinical trial. Cost data were extracted from a database provided by the Health Insurance Review & Assessment Service, and the utilization of healthcare services was estimated from an expert panel of orthopedic surgeons using a structured questionnaire. The incremental cost-effectiveness ratio (ICER) in terms of quality-adjusted life-years (QALY) was calculated. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: In the base case, the incremental costs of US$14,410 for hUCB-MSC therapy along with its associated QALY gain of 0.857 resulted in an ICER of US$16,812 (₩18,790,773) per QALY (95% confidence interval [CI] US$13,408-US$20,828) when compared with microfracture treatment from a healthcare payer perspective. From a societal perspective, the ICER was US$268 (₩299,255) per QALY (95% CI -US$2915 to US$3784). When using a willingness-to-pay threshold of US$22,367/QALY, the probability of hUCB being cost effectiveness compared with microfracture was 99% from the healthcare payer perspective and 100% from the societal perspective. CONCLUSIONS: The study demonstrated that hUCB-MSC therapy was cost effective compared with microfracture when treating patients with knee OA. These findings should inform health policy decision makers about considerations for cost-effective therapy for treating knee OA to ultimately enhance population health.
Authors: Olivier Bruyère; Germain Honvo; Nicola Veronese; Nigel K Arden; Jaime Branco; Elizabeth M Curtis; Nasser M Al-Daghri; Gabriel Herrero-Beaumont; Johanne Martel-Pelletier; Jean-Pierre Pelletier; François Rannou; René Rizzoli; Roland Roth; Daniel Uebelhart; Cyrus Cooper; Jean-Yves Reginster Journal: Semin Arthritis Rheum Date: 2019-04-30 Impact factor: 5.532
Authors: Marianna Vitaloni; Angie Botto-van Bemden; Rosa Maya Sciortino Contreras; Deborah Scotton; Marco Bibas; Maritza Quintero; Jordi Monfort; Xavier Carné; Francisco de Abajo; Elizabeth Oswald; Maria R Cabot; Marco Matucci; Patrick du Souich; Ingrid Möller; Guy Eakin; Josep Verges Journal: BMC Musculoskelet Disord Date: 2019-10-27 Impact factor: 2.362
Authors: Merel L Kimman; Carmen D Dirksen; Philippe Lambin; Liesbeth J Boersma Journal: Health Qual Life Outcomes Date: 2009-02-07 Impact factor: 3.186
Authors: Aliasghar A Kiadaliri; Carl Johan Lamm; Maria Gerhardsson de Verdier; Gunnar Engström; Aleksandra Turkiewicz; L Stefan Lohmander; Martin Englund Journal: Health Qual Life Outcomes Date: 2016-08-26 Impact factor: 3.186